{"name":"ikfe-CRO GmbH","slug":"ikfe-cro-gmbh","ticker":"","exchange":"","domain":"ikfecrogmbh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Metformin and Saxagliptin","genericName":"Metformin and Saxagliptin","slug":"metformin-and-saxagliptin","indication":"Type 2 diabetes mellitus","status":"marketed"}]}],"pipeline":[{"name":"Metformin and Saxagliptin","genericName":"Metformin and Saxagliptin","slug":"metformin-and-saxagliptin","phase":"marketed","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while saxagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.","indications":["Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}